Literature DB >> 29417654

Prevalence of adverse pathological features in 1 to 4 cm low-risk differentiated thyroid carcinoma.

Samskruthi P Murthy1, Deepak Balasubramanian1, Narayana Subramaniam1, Gopalakrishnan Nair2, Misha J C Babu2, Priyank V Rathod1, Krishnakumar Thankappan1, Subramania Iyer1, Smitha Nalumackal Vijayan3, Chaya Prasad3, Vasantha Nair4.   

Abstract

BACKGROUND: The American Thyroid Association (ATA) recommends thyroid lobectomy for 1 to 4 cm tumors without adverse features. We studied the prevalence of adverse pathological features in patients eligible for unilateral lobectomy.
METHODS: We conducted a retrospective study of patients who underwent total thyroidectomy. Patients with differentiated thyroid cancer (DTC) with tumors measuring 1 to 4 cm with no known preoperative adverse features were included in this study. Patients with nodal and distant metastasis, tumors <1 cm to > 4 cm, age < 17 years old, and gross extrathyroidal extension were excluded. Patients with bilateral nodularity on imaging were excluded from the final analysis on adverse features.
RESULTS: There were 59.1% of patients undergoing thyroidectomy with tumors measuring 1 to 4 cm and no preoperatively known adverse features who were eligible for lobectomy under current ATA guidelines who would have needed a completion thyroidectomy after pathological analysis of the index tumor.
CONCLUSION: Two thirds of the patients may require a completion thyroidectomy if unilateral lobectomy is done in tumors measuring 1 to 4 cm based on adverse pathological features.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  carcinoma; hemithyroidectomy; pathology; surgery; thyroidectomy

Mesh:

Year:  2018        PMID: 29417654     DOI: 10.1002/hed.25099

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  6 in total

Review 1.  Total thyroidectomy versus thyroid lobectomy in the treatment of papillary carcinoma.

Authors:  Marco Raffaelli; Serena Elisa Tempera; Luca Sessa; Celestino Pio Lombardi; Carmela De Crea; Rocco Bellantone
Journal:  Gland Surg       Date:  2020-01

2.  The incidence of postoperative re-stratification for recurrence in well-differentiated thyroid cancer-a retrospective cohort study.

Authors:  Narin N Carmel Neiderman; Irit Duek; Adi Ravia; Ronel Yaka; Anton Warshavsky; Barak Ringel; Nidal Muhanna; Gilad Horowitz; Tomer Ziv Baran; Dan M Fliss
Journal:  Gland Surg       Date:  2021-08

3.  Modulating the extension of thyroidectomy in patients with papillary thyroid carcinoma pre-operatively eligible for lobectomy: reliability of ipsilateral central neck dissection.

Authors:  M Raffaelli; C De Crea; L Sessa; S E Tempera; G Fadda; A Pontecorvi; R Bellantone
Journal:  Endocrine       Date:  2020-08-20       Impact factor: 3.633

4.  The Identification of Intraoperative Risk Factors Can Reduce, but Not Exclude, the Need for Completion Thyroidectomy in Low-Risk Papillary Thyroid Cancer Patients.

Authors:  Steven J Craig; Andrew M Bysice; Steven C Nakoneshny; Janice L Pasieka; Shamir P Chandarana
Journal:  Thyroid       Date:  2020-01-09       Impact factor: 6.568

5.  Clinical Characteristics-Assisted Risk Stratification for Extent of Thyroidectomy in Patients With 1-4 cm Solitary Intrathyroidal Differentiated Thyroid Cancer.

Authors:  Fang Dong; Lin Zhou; Shuntao Wang; Jinqian Mao; Chunping Liu; Wei Shi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-08       Impact factor: 5.555

Review 6.  Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer.

Authors:  Dana M Hartl; Joanne Guerlain; Ingrid Breuskin; Julien Hadoux; Eric Baudin; Abir Al Ghuzlan; Marie Terroir-Cassou-Mounat; Livia Lamartina; Sophie Leboulleux
Journal:  Cancers (Basel)       Date:  2020-11-06       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.